Ali Aminian, ESC 2021 – Obesity and COVID-19

Dr Ali Aminian (Director, Bariatric and Metabolic Institute, Cleveland Clinic, Cleveland, OH, USA) kindly shared his thoughts on the association between obesity and COVID-19 and the results of his study on the association of prior metabolic surgery and bariatric surgery with COVID-19 severity from the virtual ESC Congress 2021. Questions What have we learned about […]

Darryl Leong, ESC 2021 – Cardiometabolic Risk Factors and COVID-19

Dr Darryl Leong (Cardiologist, The Population Health Research Institute, McMaster University, Hamilton, ON, Canada) kindly shared his thoughts on the association between cardiometabolic risk factors and COVID-19 outcomes from the virtual ESC Congress 2021. Questions What has recent data taught us about the association between cardiometabolic risk factors and COVID-19 outcomes? (0.15) On the basis […]

Gilles Montalescot, ESC 2021 – the QUORUM Clinical Study

Prof. Gilles Montalescot (Professor, Pitié-Salpêtrière Hospital, Paris, France) kindly shared his thoughts on the difficulty of treating heart failure after acute myocardial infarction, the use of firibastat and the QUORUM clinical study (NCT03715998) from the virtual ESC Congress 2021. Questions Why does heart failure after acute myocardial infarction remain so challenging to treat? (0.19) Could […]

Trudie Lobban, HRC 2021 – the A-A Heart Rhythm Congress 2021

Trudie Lobban (Founder and Trustee of the Arrhythmia Alliance, Chair of the HRC Organising Committee) introduces the A-A Heart Rhythm Congress 2021 (launching 3rd October 2021) and provides an overview of what to expect from this year’s meeting, why healthcare professionals should register, who can attend, and why the virtual platform will make this the […]

COVID-19 and Cardiac Arrhythmias

European Journal of Arrhythmia & Electrophysiology. 2021;7(1):33-39 DOI: https://doi.org/10.17925/EJAE.2021.7.1.33

The current outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has developed into a worldwide pandemic affecting millions of lives in one way or another.1 Over the period of 1 year since the disease was first reported from Wuhan, China,2 COVID-19 has infected over 50 million patients and resulted […]

Medical Therapy for Secondary Prevention of Atherothrombotic Events in Peripheral Artery Disease

Heart International. 2021;15(1):14-19 DOI: https://doi.org/10.17925/HI.2021.15.1.14

Peripheral artery disease (PAD) is a severe manifestation of systemic atherosclerotic disease that commonly refers to lower-extremity arterial involvement. The global burden of PAD is estimated to involve over 200 million patients, with prevalence increasing by 24% over the past decade.1 In contrast to myocardial infarction and stroke, which are declining in the USA, the […]

Dual Antiplatelet Therapy in Patients with High Cardiovascular Risk

Heart International. 2021;15(1):26-36 DOI: https://doi.org/10.17925/HI.2021.15.1.26

Coronary artery disease (CAD) is encountered on a daily basis in the field of medicine. Between 2009 and 2012, the global prevalence of CAD was 154 million, based on data from the Global Burden of Disease study; for the same period in the USA, it was approximately 15.5 million, based on data collected by the […]

The Role of Rilonacept in Recurrent Pericarditis

Heart International. 2021;15(1):20-25 DOI: https://doi.org/10.17925/HI.2021.15.1.20

Pericarditis is the most common form of pericardial disease, with an incidence of 27.7 cases per 100,000 population per year.1 Approximately 15–30% of patients with acute pericarditis will have a first recurrence within 18 months despite optimal medical therapy. Half of these patients will fail to achieve complete remission and will continue to have recurrent […]